Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
Information source: mAbxience S.A
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Metastatic Colorectal Cancer.
Intervention: Bevacizumab biosimilar (BEVZ92) (Drug); Avastin® (bevacizumab, reference product) (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: mAbxience S.A Overall contact: Pilar Sanjuan Sanz, MSc, Phone: + 34 91 771 15 00, Ext: 9575, Email: pilar.sanjuan@mabxience.es
Summary
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab
biosimilar) and Avastin® with 2 parallel arms to compare the PK profile of BEVZ92 and
Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy.
FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital
standard of care.
Clinical Details
Official title: Open Label Randomized Bioequivalence Study to Evaluate the PK and Safety Profile of Bevacizumab Biosimilar (BEVZ92) With FOLFOX or FOLFIRI vs Bevacizumab (AVASTIN®) With FOLFOX or FOLFIRI in First-line Treatment for mCRC Patients
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI
Secondary outcome: Safety, immunogenicity and efficacy profile
Detailed description:
Planned enrolment duration: 12 months. Pre-treatment period (included in enrolment period):
1 month. Treatment period: Patients will continue treatment until disease progression or
unacceptable toxicity, or withdrawal of consent.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Patient must not have had prior chemotherapy for advanced or metastatic disease.
Patients could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy.
2. Patient with mCRC for whom bio-chemotherapy is indicated.
3. Patients must have at least one measurable non-irradiated site of disease according
to RECIST (version 1. 1) criteria. If the patient has had previous irradiation of the
marker lesion(s), there must be evidence of progression since the radiation.
4. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of
all prior systemic anticancer therapy
5. ECOG performance status ≤ 2.
6. Adequate bone marrow function
7. Adequate liver function defined within specific parameters
8. Adequate renal function defined within specific parameters
9. Adequate coagulation parameters defined within specific parameters
10. Negative pregnancy test for females of a childbearing potential.
11. Use of an effective form of contraception during the study (for subjects of
childbearing potential and their partners).
12. Life expectation ≥ 3 months
Exclusion Criteria:
1. Prior treatment for advanced or metastatic colorectal cancer.
2. Prior treatment with an anti-angiogenesis agent, in either the neoadjuvant or
adjuvant setting.
3. Concurrent use of investigational anti-neoplastic agents (including up to 4 weeks
prior to enrolment).
4. History of any other malignancy unless the malignancy is in complete remission and
the patient has been off all therapy for that malignancy for at least 5 years.
5. Chronic treatment with systemic steroids or other immunosuppressive agents; topical
or inhaled corticosteroids are allowed.
6. Scheduled immunization with attenuated live vaccines during study period or within 1
week prior to study entry.
7. Uncontrolled brain or lepto-meningeal metastases, including patients who continue to
require glucocorticoids for brain or lepto-meningeal metastases.
8. Patients with active bleeding or history of bleeding diathesis on oral anti-vitamin K
medication (except low dose coumadin) within the past 6 month prior to randomization
or coagulopathy.
9. Patients with history of cerebral vascular accident, transient ischemic attack, or
subarachnoid haemorrhage within the past 6 month prior to randomization.
10. Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study
11. Patients with serious non-healing wound, ulcer, bone fracture, or with a major
surgical procedure, or significant traumatic injury within 4 weeks prior to
randomization
12. Patients with clinical symptoms or signs of gastrointestinal obstruction that require
parenteral hydration and/or nutrition.
13. Patients with history of abdominal fistula, gastrointestinal perforation, or
intra-abdominal abscess within the past 6 months prior to randomization.
14. Patients with history of hypersensitivity to any of the study drugs or ingredients.
Locations and Contacts
Pilar Sanjuan Sanz, MSc, Phone: + 34 91 771 15 00, Ext: 9575, Email: pilar.sanjuan@mabxience.es
Hospital de Gastroenterologia "Dr. Carlos Bonorino Udaondo", Buenos Aires, Argentina; Recruiting
Instituto Oncológico de Rosario, Rosario, Argentina; Recruiting
Fundaçáo Pio XII - Hospital do Cancer de Barretos, Barretos, Brazil; Recruiting
Hospital Caridade, Ijui, Brazil; Recruiting
Hospital Sao Lucas da Pucrs, Porto Alegre, Brazil; Not yet recruiting
Hosp. A.C Camargo, Sao Paolo, Brazil; Not yet recruiting
Instituto do Cancer del estado de S. Paulo (ICEPS ), Sao Paulo, Brazil; Recruiting
Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC, São Paulo, Brazil; Recruiting
Sri Ramachandra Hospital, Chennai, India; Recruiting
M S Patel Cancer Centre- Shree Krishna Hospital, Karamsand, India; Recruiting
Tata Hospital, Mumbai, India; Recruiting
Central India Canter Research Institute, Nagpur, India; Not yet recruiting
Curie Manavta Cancer Center, Nashik, India; Recruiting
Regional Cancer Center & Medical College, Thiruvananthapuram, India; Recruiting
Centro Oncológico Clara Campal, Madrid, Spain; Recruiting
Dnipropetrovsk City Multiple-discipline Clinical Hospital â„–4, Dnipropetrovsk, Ukraine; Recruiting
Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine; Recruiting
Danylo Halytskiy Lviv National Medical University, Lviv, Ukraine; Recruiting
Additional Information
Starting date: October 2014
Last updated: August 11, 2015
|